We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




PerkinElmer Collaborates on Preterm Birth Biomarkers

By HospiMedica staff writers
Posted on 21 Aug 2006
Print article
PerkinElmer, Inc. (Wellesley, MA, USA) has announced a multi-year license-and-research agreement with the University of Leicester (Leicester, United Kingdom) under which the two organizations will begin to lay the groundwork for the clinical investigation and discovery of biomarkers that predict preterm birth (PTB). The collaboration will be financed by PerkinElmer.

PerkinElmer will support the expansion of the University of Leicester's maternal health research capabilities and provide advanced tools, technology, and expertise. Professor J. C. Konje, M.D., and colleagues of Leicester University's reproductive sciences section of the department of cancer studies and molecular medicine are dedicated to the study and prediction of preterm birth. The team is conducting research in the field of preterm labor diagnosis.

The partnership will give PerkinElmer broader access within Professor Konje's research group to clinical samples, methodology, and clinical consultancy support in the field of maternal health. The University of Leicester and PerkinElmer will work towards validating any new PTB biomarkers that will complement PerkinElmer's maternal health portfolio. PerkinElmer and the University of Leicester will share access to licensed intellectual property from new PTB biomarkers that result from this research.

It is estimated that preterm labor complicates 6-10% of all pregnancies and is the most common cause of neonatal morbidity and mortality. Worldwide statistics reflect that there may be as many as 13 million preterm births annually, and this figure is predicted to increase. In the United States alone, an estimated U.S.$820 million is spent on preterm hospitalization subsequently shown to have been unnecessary. These hospitalizations tax both the mother's health and healthcare resources.

Currently, there are no rapid or accurate tests that positively predict preterm labor. The aim of the collaboration between PerkinElmer and the University of Leicester is to effectively address this need and eventually design and supply an effective preterm labor test predictor.



Related Links:
PerkinElmer
University of Leicester
Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
Chemistry Analyzer
MS100

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.